Literature DB >> 11884907

Efficacy of the transcutaneous electrical nerve stimulation for the treatment of chronic low back pain: a meta-analysis.

Lucie Brosseau1, Sarah Milne, Vivian Robinson, Serge Marchand, Beverley Shea, George Wells, Peter Tugwell.   

Abstract

BACKGROUND: Low back pain affects a large proportion of the population. Transcutaneous electrical nerve stimulation (TENS) was introduced more than 30 years ago as an alternative therapy to pharmacologic treatments for chronic pain. However, despite its widespread use, the efficacy of TENS is still controversial.
PURPOSE: The aim of this meta-analysis was to determine the efficacy of TENS in the treatment of chronic low back pain.
METHODS: The authors searched MEDLINE, EMBASE, PEDro, and the Cochrane Controlled Trials Register up to June 1, 2000. Only randomized controlled clinical trials of TENS for the treatment of patients with a clinical diagnosis of chronic low back pain were included. Abstracts were excluded unless further data could be obtained from the authors. Two reviewers independently selected trials and extracted data using predetermined forms. DATA ANALYSIS: Heterogeneity was tested with Cochrane's Q test. A fixed effects model was used throughout for continuous variables, except where heterogeneity existed, in which case, a random effects model was used. Results are presented as weighted mean differences with 95% confidence intervals, where the difference between the treated and control groups was weighted by the inverse of the variance. Standardized mean differences were calculated by dividing the difference between the treated and control by the baseline variance. Standardized mean differences were used when different scales were integrated to measure the same concept. Dichotomous outcomes were analyzed with odds ratios. MAIN
RESULTS: Five trials were included, with 170 subjects randomized to the placebo group receiving sham TENS and 251 subjects receiving active TENS (153 for conventional mode, 98 for acupuncture-like TENS). The schedule of treatments varied greatly between studies ranging from one treatment/day for 2 consecutive days, to three treatments/day for 4 weeks. There were no statistically significant differences between the active TENS group compared with the placebo TENS group for any outcome measures. Subgroup analysis performed on TENS application and methodologic quality did not demonstrate a significant statistical difference (P > 0.05). Remaining preplanned subgroup analysis was not conducted because of the small number of included trials and the variety of outcome measures reported.
CONCLUSION: The results of the meta-analysis present no evidence to support the use or nonuse of TENS alone in the treatment of chronic low back pain. Considering the small number of studies responding to the criteria to be included in this meta-analysis, it is clear that more appropriately designed studies are needed before a final conclusion. Clinicians and researchers should consistently report the characteristics of the TENS device and the application techniques used. New trials on TENS should make use of standardized outcome measures. This meta-analysis lacked data on how TENS efficacy is affected by four important factors: type of applications, site of application, treatment duration of TENS, and optimal frequencies and intensities.

Entities:  

Mesh:

Year:  2002        PMID: 11884907     DOI: 10.1097/00007632-200203150-00007

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  22 in total

1.  Comparison of three different approaches in the treatment of chronic low back pain.

Authors:  Sebnem Koldaş Doğan; Birkan Sonel Tur; Yeşim Kurtaiş; Mesut Birol Atay
Journal:  Clin Rheumatol       Date:  2008-01-11       Impact factor: 2.980

Review 2.  Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain.

Authors:  Amole Khadilkar; Daniel Oluwafemi Odebiyi; Lucie Brosseau; George A Wells
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

3.  Single-lead percutaneous peripheral nerve stimulation for the treatment of hemiplegic shoulder pain: a case series.

Authors:  John Chae; Richard D Wilson; Maria E Bennett; Tina E Lechman; Kathryn W Stager
Journal:  Pain Pract       Date:  2012-03-26       Impact factor: 3.183

Review 4.  Variation in eligibility criteria from studies of radiculopathy due to a herniated disc and of neurogenic claudication due to lumbar spinal stenosis: a structured literature review.

Authors:  Stephane Genevay; Steve J Atlas; Jeffrey N Katz
Journal:  Spine (Phila Pa 1976)       Date:  2010-04-01       Impact factor: 3.468

5.  Effect of Mulligan Concept Lumbar SNAG on Chronic Nonspecific Low Back Pain.

Authors:  Hisham Mohamed Hussien; Neveen Abdellatif Abdel-Raoof; Omaima Mohamed Kattabei; Hassan Hussien Ahmed
Journal:  J Chiropr Med       Date:  2017-03-30

6.  Clinical Effect of End-range Maitland Mobilization in the Management of Knee Osteoarthritis - A Pilot Study.

Authors:  Miklós Pozsgai; Erzsébet Kövesdi; Balázs Németh; István Kiss; Nelli Farkas; Tamás Atlasz; Márk Váczi; Nóra Nusser
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

Review 7.  Chronic non-malignant musculoskeletal pain in older adults: clinical issues and opioid intervention.

Authors:  V K Podichetty; D J Mazanec; R S Biscup
Journal:  Postgrad Med J       Date:  2003-11       Impact factor: 2.401

8.  Spinal cord stimulation for neuropathic pain: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-03-01

9.  Blockade of NMDA receptors prevents analgesic tolerance to repeated transcutaneous electrical nerve stimulation (TENS) in rats.

Authors:  Priyanka M Hingne; Kathleen A Sluka
Journal:  J Pain       Date:  2007-12-03       Impact factor: 5.820

10.  Effect of Laser Therapy on Chronic Osteoarthritis of the Knee in Older Subjects.

Authors:  Enas Fawzey Youssef; Qassim Ibrahim Muaidi; Alsayed Abdelhameed Shanb
Journal:  J Lasers Med Sci       Date:  2016-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.